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Early graft function and patient survival following cadaveric renal failure, it is less certain whether it improves long-
renal transplantation. term survival [1–3]. Currently, death with a functioning
Background. The influence of events that occur early follow- transplant and chronic rejection are the main causes ofing renal transplantation such as delayed graft function (DGF)
graft loss following transplantation [4]. Cardiovascularand acute rejection on long-term graft survival has been widely
disease, infection, and malignancy are the principalreported, but its association with patient survival has received
less attention. causes of death in renal transplant recipients [5–7], but
Methods. We studied 589 patients who received their first the factors influencing patient survival have not been
cadaveric transplants between 1984 and 1993, all of whom
widely studied. Although acute rejection [8–10], poorreceived cyclosporine-based immunosuppression and who had
early graft function [11–13], and possibly delayed grafta median follow-up of seven years. The following factors were
identified, and both univariate and multivariate analyses were function (DGF) [11–14] may have an adverse effect on
used to determine their association with long-term patient and long-term graft survival, their association with patient
graft survival: age, sex, duration of pretransplant dialysis, pri- survival is unclear. A study of the UNOS Scientific Renalmary renal disease, immediate graft function (IGF), DGF, pri-
Transplant registry [15] has reported significantly highermary nonfunction (PNF), acute rejection, and serum creatinine
death rates among recipients with DGF or early rejec-at 3, 6, and 12 months.
Results. Patients with PNF had a poorer survival than those tion. Adverse patient survival has also been shown in
with DGF and IGF (P 5 0.01), but there was no difference in patients with DGF in combination with rejection [16].
survival between DGF and IGF (P 5 0.54). Good graft function
This analysis was carried out in an attempt to clarify the(serum creatinine of less than 200 mmol/liter) at three months
association of events that occur early following renalwas predictive of better long-term patient survival (P 5 0.03).
Other factors associated with poor patient outcome were older transplantation on long-term patient outcome.
age, diabetes, adult polycystic kidney disease, male gender, and
acute rejection. Cardiovascular disease was the most common
cause of death (51.8%). Good graft function at three months METHODS
(P , 0.001) and an absence of rejection episodes (P 5 0.01)
Patientswere associated with better graft survival.
Conclusion. Patients with poor levels of early graft function Six hundred thirty-three consecutive first cadaveric
(but not DGF) and those with either acute rejection episodes transplants were performed in our center between 1 Jan-
or early graft loss are at an increased risk of early death. These
uary, 1984, to 31 December, 1993. None of these trans-high-risk groups should be targeted for interventional studies
plants were preemptive, and we excluded patients whoin an attempt to improve patient survival.
were under the age of 16 years (37 patients), those who
did not receive cyclosporine as part of their immunosup-
Although renal transplantation offers a better quality pressive regimen at the time of transplantation (five pa-
of life than dialysis for many patients with end-stage tients), and those whose care was transferred to other
renal units (two patients). The remaining 589 patients
were included in the analysis.Key words: transplant survival, allograft function, cardiovascular
death, acute rejection, delayed graft function, primary non-function.
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kg. During the transplant operation, 1 g of methylpred- Statistical analysis
nisolone was given intravenously. Thereafter, the daily Two survival outcomes, patient and graft survival,
cyclosporine dosage was guided by trough cyclosporine were analyzed. Patient survival was defined from date
levels, aiming for a target of 200 to 300 ng/ml in the first of transplant until date of death. Patients who were alive
two weeks, with a steady decrement in the target blood at 1 August 1997, were censored. For the purpose of
level to 80 to 140 ng/ml after 12 months. Oral predniso- graft survival analysis, graft failure was defined as return
lone in a dose of 20 mg per day was continued for the to dialysis, and death with a functioning graft was
first month, and the dose was then reduced to reach 10 counted as lost to follow-up. A further analysis of graft
mg daily at 12 months, whereas those on azathioprine survival was carried out including death as graft failure.
continued this drug in a dose of 1 to 1.5 mg/kg/day unless Kaplan-Meier survival curves were computed for all
leukopenia developed. Between 1985 and 1991, 216 of primary factors of interest. The log-rank test was used
the 589 patients who initially received only prednisolone to assess the significance of differences in survival. A
and cyclosporine were randomized at one-year post- Cox proportional hazards model with adjustment for
transplant to continue on this regimen or to convert to gender, age (,20, 20–29, 30–39, 40–49, 50–59, .60), and
prednisolone and azathioprine. Conversion did not alter primary renal disease (diabetes, glomerulonephritis,
chronic pyelonephritis, adult polycystic kidney disease,long-term graft or patient survival significantly in this
hypertensive nephrosclerosis, all other diagnoses) wasstudy [17], and these patients are, therefore, included in
then used to assess the prognostic value of early eventsthis analysis.
post-transplantation and of the level of graft function on
Definitions long-term patient and graft survival.
Finally, the chi-square test was applied to compare dif-Patients who did not require dialysis following trans-
ferences in frequency of events in the different groups, andplantation were defined as having immediate graft func-
the Kruskall-Wallis test was applied for continuous data.tion (IGF); DGF was defined as the need for one or
more hemodialysis treatments following transplantation
prior to the onset of graft function. The duration of DGF RESULTS
was calculated from the date of transplantation to the
Five hundred eighty-nine patients were included indate of the last dialysis treatment. Patients whose grafts
the analysis, with a median follow-up time of seven years.never functioned were defined as having primary non-
Patient demographics in the three groups are shown infunction (PNF). This group included patients who had
Table 1. Sixty-one percent had IGF (N 5 360), 31%
vascular or ureteric operative complications, vascular
DGF (N 5 181), and 8% PNF (N 5 48). Age, sex, and
thrombosis, hyperacute rejection, and “nonviable” kid- the distribution of primary renal disease were similar in
neys. all groups. However, the group with PNF had signifi-
cantly longer duration of renal replacement therapy priorAcute allograft rejection
to transplantation than those with IGF and DGF (P ,
Rejection episodes were defined on the basis of treat- 0.0001).
ment with a course of high-dose corticosteroids and/or The causes of graft failure in the 48 patients with PNF
antilymphocyte therapy. In our center, it was routine were vascular or ureteric operative problems (43.7%),
practice for our patients to be biopsied to confirm acute irreversible acute rejection (41.7%), vascular thrombosis
rejection prior to commencing treatment unless there unrelated to operative problems (6.2%), “nonviable”
was a contraindication. Patients with DGF were moni- kidney (2.1%), hyperacute rejection (2.1%), and miscel-
tored by serial Doppler ultrasound and technetium iso- laneous (4.2%).
tope scans as an aid to detect rejection [18], which was The number of patients with at least one episode of
then confirmed or excluded by transplant biopsy. acute rejection was 51% (N 5 301). During the period
of follow-up, 195 patients (64.8%) had one rejection
Data collection episode. Seventy-eight (25.9%) had two episodes.
All patients were followed until death or 1 August Twenty-two (7.3%) had three episodes, and six (2%)
1997, whichever occurred first. Data were collected from patients had four rejection episodes. The group with one
the computerized clinical records, which are updated or more rejection episode had a median age of 39 years
daily in the immediate postoperative period and subse- (interquartile range of 31 to 51), whereas those without
quently at each follow-up clinic visit, and additional in- rejection were older with a median age of 48 years (34
formation was obtained from the patient’s case record. to 56; P , 0.001).
A number of items of donor information have been pre- Acute rejection episodes were more common (63% vs.
viously studied in our center [19] and did not form part 49%, P , 0.01) and occurred earlier (median time of 10
days vs. 22 days, P , 0.01) in patients with DGF comparedof this analysis.
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Table 1. Patient demographics
Immediate graft Delayed graft Primary non-
Recipient variables function (IGF) function (DGF) function (PNF)
Number % 360 (61%) 181 (31%) 48 (8%)
Mean age at transplantation years 44 (17–65)a 46 (16–66)a 42 (17–70)a
Sex ratio male:female 60:40 60:40 65:35
Median duration on dialysis prior to transplantation months 17 (2.7–134)a 19 (2.2–197)a 28 (5.4–118)a,b
Primary renal diagnosisc
Diabetes mellitus 31 (8.6%) 15 (8.3%) 7 (14.6%)
Glomerulonephritis 102 (28.3%) 57 (31.5%) 13 (27.1%)
Chronic pyelonephritis/interstitial nephritis 83 (23%) 37 (20.4%) 5 (10.4%)
Adult polycystic kidney disease 46 (12.8%) 16 (8.8%) 4 (8.3%)
Hypertensive nephrosclerosis 25 (6.9%) 14 (7.7%) 6 (12.5%)
All other diagnoses 73 (20.3%) 42 (23.3%) 13 (27.1%)
a Associated ranges
b PNF group had significantly longer duration on dialysis prior to transplantation (P , 0.0001)
c The distribution of primary renal disease was not significantly different between the three groups
with those with IGF. However, in those who had rejection When univariate analysis was performed on a sub-
group of 502 patients after excluding those with earlyin the IGF group, 57 (32.2%) patients had their first epi-
sode more than 90 days after transplantation compared graft failure or death within 90 days, good graft function
was associated with long-term patient survival (Fig. 1B).with 14 (12.3%) patients in the group with DGF.
This effect was seen as early as three months after trans-
Patient survival plantation, where patients with serum creatinine of less
than 200 mmol/liter had the best survival, followed byDuring follow-up, 168 patients (28.5%) died; 89 (53%)
those with creatinine levels of 200 to 400 mmol/liter,with functioning grafts, and 79 (47%) died after their
and the worst survival was noted in those with serumgrafts had failed. Death rates were similar in patients
creatinine levels of more than 400 mmol/liter (P 5 0.03;with IGF (26.1%) and DGF (29.3%) but were higher in
Fig. 1B). This association remained significant on multi-the PNF group (43.8%). Cardiovascular disease was the
variate analysis (Table 3). Median time of patient sur-most common cause of death (N 5 87, 51.8%), whereas
vival for those with three-month serum creatinine of lessthe other causes were infection (N 5 17, 10%), malig-
than 200 mmol/liter was 6.93 years compared with 4.68nancy (N 5 15, 9%), miscellaneous (N 5 10, 6%), and
years for the group who had returned to dialysis. Aunknown in 23.2% (N 5 39).
similar effect on patient survival was evident when uni-Actuarial patient survival for the total population was
variate analysis was performed using serum creatinine95% at one year, 82% at five years, and 65% at 10 years.
values at 6- and 12-months post-transplantation.Predicted long-term patient survival was better in the
An adverse effect of rejection episodes on patient sur-group with functioning grafts (85% at five years, 70%
vival in the long term was not apparent on Kaplan-Meierat 10 years) than for those whose grafts had failed (75%
analysis (P 5 0.27). However, when serum creatinineat five years, 56% at 10 years; log-rank test, P 5 0.004).
was excluded from the multivariate analysis (as thereUnivariate analysis of patient survival in the 589 pa-
was an interaction between graft function and rejection),tients when divided by early graft function is shown in
this effect of rejection episodes was significant (P 5Figure 1A. Survival was not significantly different in the
0.02). Table 4 summarizes the results of this analysis.patients with IGF and DGF (P 5 0.54), but PNF had
Other factors associated with poorer patient survivalan adverse effect on survival (P 5 0.01). No deaths in
were increasing age at time of transplantation, male gen-this group occurred during the period of graft non-func-
der, and a primary renal diagnosis of diabetes and adulttion, and the median time from transplant to death was
polycystic kidney disease.1.5 years (range 22 days to 6.2 years), with only 2 of the
20 patients dying within 90 days post-transplantation.
Graft survivalThe association of PNF with a poorer outcome was con-
firmed on multivariate analysis when adjustments were Actuarial graft survival for the total population was
84% at one year, 68% at five years, and 55% at 10 yearsmade for recipient age, gender, and primary renal disease
(Table 2). After controlling for the effect of early graft when death with a functioning graft was censored. When
such deaths were counted as graft loss, graft survival wasfunction, including PNF, age, gender, and primary renal
disease, the influence of time on renal replacement ther- 81% at one year, 60% at five years, and 45% at 10 years.
The following results consider death with a functioningapy prior to transplantation was not significant (P 5
0.54) and was thus excluded from the model. graft as censored.
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Table 2. Cox regression analysis for patient survival
Early graft function Hazard ratio (95% confidence)
Immediate function 1.00 (baseline)
Delayed graft function 1.04 (0.74 to 1.47)
Primary non-function 2.04 (1.24 to 3.37)
Patient survival: Hazard ratios (95% confidence interval) for early graft func-
tion were adjusted for gender, age and primary renal disease. Results are based
on 589 patients.
Table 3. Cox regression analysis for patient and graft survival
Hazard ratio (95% confidence)
Serum creatinine at
3 months Patient survival Graft survival
,200 mmol/liter 1.00 (baseline) 1.00 (baseline)
200–400 mmol/liter 1.75 (1.05 to 2.89) 2.97 (1.94 to 4.54)
.400 mmol/liter 1.72 (0.69 to 4.29) 9.74 (4.61 to 20.54)
Hazard ratios (95% confidence interval) for serum creatinine at 3 months
post-transplantation were adjusted for gender, age and primary renal disease.
Results are based on 502 patients (excluding those with graft failure and deaths
within 3 months of receiving a transplant).
Graft survival of patients with no acute rejection epi-
sodes was significantly better than for those with one or
more episodes with median survival times of 5.4 years
and 3.94 years, respectively (P 5 0.01). The median time
to development of the first episode of acute rejection
was 11 days after transplantation. Long-term survival of
grafts that underwent acute rejection within 11 days post-
transplantation was significantly better than those whose
first rejection episode occurred after 11 days (P 5 0.002).
Graft survival was inversely correlated to the number of
episodes of rejection such that the patients with one
rejection episode had a better outcome that those with
multiple episodes (P , 0.001). There was no significant
difference in graft survival between patients with IGF
without rejection versus DGF without rejection (P 5
0.12) and IGF with rejection versus DGF with rejection
(P 5 0.15). However, the two groups with acute rejection
had poorer survival than those without.
Figure 2B shows the effect of graft function, based on
the serum creatinine values at three months, on long-
term graft survival (excluding all grafts that were non-
Fig. 1. Patient survival. (A) Kaplan Meier estimates for patients with functioning or lost through patient death in the first 90
immediate function (———; IGF, N 5 360), delayed graft function days after transplantation). The best outcome was seen
(-- - - -; DGF, N 5 181), and primary non-function (—-—-; PNF, N 5
in patients with good graft function (serum creatinine of48). Log-rank test, P 5 0.009. (B) Kaplan Meier estimates by serum
creatinine at three months. Creatinine (Cr) less than 200 mmol/liter less than 200 mmol/liter) at three-months post-trans-
(———; N 5 418), Cr 200 to 400 mmol/liter (- - - - -; N 5 73), and Cr of plantation and the worst in those with poor graft function
more than 400 mmol/liter (— - — -; N 5 12). Log-rank test, P 5 0.03.
(serum creatinine of more than 400 mmol/liter). Median
graft survival for the group with serum creatinine of less
than 200 mmol/liter was 6.13 years, 3.76 years in theThere was no difference in long-term graft survival
group with serum creatinine of 200 to 400 mmol/liter,between patients with IGF and those with DGF (P 5
and 1.37 years in those with serum creatinine of more0.51; Fig. 2A). In those patients who experienced DGF,
than 400 mmol/liter. A similar effect on long-term graftthe median time to onset of function was 10 days. Actuar-
survival was seen for serum creatinine at 6- and 12-ial graft survival did not differ between those grafts that
started functioning before and after 10 days (P 5 0.86). months post-transplantation.
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Table 4. Cox regression analysis for patient and graft survival
Hazard ratio (95% confidence)
Factor Patient survival Graft survival
Acute rejection status
no rejection 1.00 (baseline) 1.00 (baseline)
rejection 1.52 (1.04 to 2.20) 1.46 (1.04 to 2.06)
Gender
Male 1.00 (baseline) 1.00 (baseline)
Female 0.66 (0.44 to 0.98) 0.91 (0.64 to 1.29)
Age
20–29 0.17 (0.07 to 0.39) 1.43 (0.85 to 2.42)
30–39 0.37 (0.22 to 0.65) 1.31 (0.79 to 2.17)
40–49 0.52 (0.32 to 0.84) 0.86 (0.50 to 1.48)
50–59 1.00 (baseline) 1.00 (baseline)
601 1.57 (0.93 to 2.64) 0.75 (0.34 to 1.67)
Primary renal disease
Diabetes 3.66 (2.06 to 6.48) 1.61 (0.87 to 3.00)
Glomerulonephritis 1.00 (baseline) 1.00 (baseline)
Chronic pyelonephritis 1.54 (0.88 to 2.69) 1.14 (0.72 to 1.79)
Adult polycystic kidney disease 1.89 (1.02 to 3.52) 1.23 (0.64 to 2.37)
Hypertensive nephrosclerosis 1.23 (0.56 to 2.70) 0.86 (0.37 to 1.97)
All other diagnoses 0.95 (0.51 to 1.74) 0.74 (0.45 to 1.22)
Hazard ratios (95% confidence interval) for rejection status were adjusted for serum creatinine at three months, gender, age and primary renal disease. Results
are based on 502 patients (excluding those with graft failure and deaths within 3 months of receiving a transplant).
When adjustments were made for recipient age, gen- complications such as infection and malignancy are re-
der, and primary renal disease on multivariate analysis sponsible for a minority of deaths (17%) in contrast to
(Table 3), the most significant factor associated with earlier studies [23–25].
long-term graft survival was the level of graft function In our population, over a third of the patients died
at three months (P , 0.001). With further adjustments within 10 years of receiving their first cadaveric trans-
made for the level of graft function at three months plant. This surprisingly high figure is explained by the
(Table 4), the occurrence of acute rejection was associ- high prevalence of cardiovascular disease in this popula-
ated with an adverse long-term survival (P 5 0.02). The tion and by the inclusion of patients who died after graft
time of onset of graft function, that is, whether IGF or failure, this group accounting for almost half of all of
DGF, and time on renal replacement therapy prior to the deaths. Previous reports that have excluded or cen-
transplantation were not of significance and thus were sored this group of patients in their analyses [26] may
excluded from the Cox model. As summarized in Table have been misleading, because our study demonstrates
4, graft outcome was not dependent on recipient age, that graft loss is associated with an increased risk of
gender, or primary renal disease. death. The fact that patients with PNF or later graft loss
are at increased risk of dying when they return to dialysis
is not unexpected, but it is of considerable clinical impor-DISCUSSION
tance.This study shows that events occurring in the early
Data from the Canadian Organ Replacement Registryperiod following renal transplantation are associated not
1990 Report have previously documented poorer sur-only with long-term graft outcome, but also with patient
vival in patients following a failed first graft [27]. Thesurvival. Increased cardiovascular mortality in patients
highest mortality was seen in those with early graft losswith end-stage renal disease is well recognized [20, 21],
(within 90 days) followed by those with later graft lossand the risk rises in proportion to the prevalence of
(after 90 days) compared with the group with functioningcardiovascular disease in the general population, which
transplants (59% vs. 72% vs. 85% at four years). How-is very high in the west of Scotland [22]. Cardiovascular
ever, 22% of their patients with early graft loss and 23%disease accounted for the majority of deaths in our study,
with late graft loss died of infective causes. In contrast,with regard to patients who died either before or after
cardiovascular disease was the predominant cause ofgraft failure. It is likely that most of those patients whose
death in our study group of patients with graft loss.cause of death was unknown (23%) also died from car-
Despite improved experience with the use of immuno-diovascular disease (as many of these patients died sud-
suppressive drugs and decreased risk of sepsis, this groupdenly at home), and thus, we have probably underesti-
of patients remains at high risk of early death. Althoughmated the true incidence of cardiovascular deaths. Our
study highlights the fact that in the cyclosporine era, it is beyond the scope of our study to identify the mecha-
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ated with poorer patient survival. Although these factors
are recognized as predictors of poor graft survival [9, 11,
12], their association with increased mortality needs to
be emphasized. A study of the North American Pediatric
Renal Transplant Cooperative Study registry [28] re-
ported graft failure and rejection within 30 days follow-
ing transplantation to be independent risk factors for
increased mortality in a pediatric population, and our
study confirms these findings in an adult population.
Kasiske et al have shown acute rejection to be a consis-
tent independent risk factor for the subsequent develop-
ment of cardiovascular disease [29]. The reason for this
remains to be clarified but may be, in part, the conse-
quence of increased exposure to immunosuppressive
drugs that have an adverse effect on conventional cardio-
vascular risk factors such as hypertension and hyperlipid-
emia [30, 31]. It is also possible that acute rejection and
its treatment lead directly to endothelial damage and
thus promote accelerated atherosclerosis [32].
We found that the level of early graft function, as
assessed by serum creatinine, is a more sensitive index
than the occurrence of acute rejection episodes in pre-
dicting patients at risk of premature death. Although
serum creatinine is not independent of other factors such
as rejection, it is the standard test for assessment of renal
function and could be used to identify patients to be
targeted for intervention. Indeed, interventional studies
to reduce mortality in renal transplant recipients that
exclude patients with poor renal function and concen-
trate on those with well functioning grafts are unlikely
to succeed, as they exclude the group at highest risk.
By contrast, univariate and multivariate analyses
showed no adverse association between DGF and long-
term patient or graft survival. DGF was relatively com-
mon (31%) in our patients but was not associated with
worse renal function at three months than in patients
with IGF. Although the long-term effect of DGF remains
controversial [11–14, 33–35], there was no deleterious
effect in our patient population. Our study has also failed
to show an association between the length of dialysis
pretransplant and patient outcome. This is not surprising
because the analysis corrected for increasing age and
because patients who developed serious comorbid illnessFig. 2. Graft survival. (A) Kaplan Meier estimates for patients with
immediate function (———; IGF, N 5 360) and delayed graft function on dialysis were likely to be taken off the active trans-
(- - - - -; DGF, N 5 181). Log-rank test, P 5 0.51. (B) Kaplan Meier plant waiting list. A study designed to assess the outcomeestimates by serum creatinine at three months. Cr of less than 200
of all patients placed on the transplant waiting list wouldmmol/liter (———; N 5 418), Cr of 200 to 400 mmol/liter (dashed line;
N 5 73), and Cr of more than 400 mmol/liter (— - — -; N 5 12). Log- be required to investigate this aspect further.
rank test, P , 0.001. As expected, increasing age and diabetes mellitus were
the strongest predictors of mortality in this study [11,
13, 16, 33]. Previous reports have noted worse survival
in male than in female transplant recipients [26], and wenism for this, it is likely to be the result of a number of
factors, including the effect of early return to dialysis have confirmed this finding. An adverse association with
polycystic kidney disease, although an unexpected find-(and uremia), and the physical trauma of major surgery.
In addition to their relationship to graft failure, acute ing, has also been previously reported [36]. The inclusion
of all deaths in our analysis may partly explain this associ-rejection and poor early graft function were also associ-
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Transplantation 61:1479–1483, 1996come, and this question cannot be answered from a retro-
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